J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?

Johnson & Johnson is attempting to change the antidepression market with its ketamine-derivative Spravato despite strict dosing requirements and a steep list price. New data in treating high-risk depression patients could help, but will physicians and payers come around?